The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,690 | -5,848 | -2,344 | -9,503 |
| Loss on impairment of intangible assets | - | 6,995 | - | - |
| Loss on debt extinguishment | - | -3,260 | - | - |
| Depreciation and amortization | 405 | 527 | 528 | 1,060 |
| Stock-based compensation | 64 | 79 | 70 | 189 |
| Amortization of operating right-of-use assets | 97 | - | - | - |
| Change in fair value of minority equity interest | -2,302 | - | - | - |
| Change in fair value of deferred consideration | 2,877 | - | - | - |
| Change in fair value of royalties payable due to related parties | 0 | 7,813 | 726 | -2,830 |
| Change in fair value of convertible notes payable | - | 2 | - | - |
| Net loss on trading debt securities | - | -681 | 107 | 10 |
| Deferred income tax provision (benefit) | -174 | -214 | 78 | -1,674 |
| Acquired in-process research and development | 0 | 0 | 0 | 1,967 |
| Amortization of discount on note payable | - | 18 | 17 | 10 |
| Accretion of discount on note payable | 28 | - | - | - |
| Accounts receivable | 105 | 32 | 8 | 45 |
| Inventories | -19 | 57 | -4 | 25 |
| Prepaid expenses and other current assets | 349 | -193 | 83 | -145 |
| Operating lease right-of-use assets and lease liabilities | -97 | 1 | -1 | -4 |
| Current portion of royalties payable due to related parties | -42 | 12 | -7 | 14 |
| Accounts payable | -514 | 492 | 303 | 361 |
| Accrued expenses | 119 | 134 | 30 | -15 |
| Deferred revenue | -45 | - | - | - |
| Interest payable-Related Party | 48 | 47 | 48 | 90 |
| Interest payable-Variable Interest Entity Not Primary Beneficiary | 15 | 15 | 15 | 9 |
| Net cash used in operating activities | -2,796 | -1,512 | -2,183 | -4,601 |
| Consideration paid for acquired in-process research and development | 103 | 82 | 28 | 6 |
| Purchases of property and equipment | 6 | 0 | 0 | 17 |
| Proceeds from the sale of trading debt securities | - | 300 | - | - |
| Acquisition, net of cash acquired | 1,210 | - | - | - |
| Net cash used in investing activities | -1,319 | 218 | -28 | -23 |
| Proceeds from issuance of series b convertible preferred stock and other equity-classified warrants, net of issuance costs-Series BConvertible Preferred Stock | - | 0 | 0 | 1,170 |
| Proceeds from issuance of common stock-September2024Public Offering | - | 0 | 0 | - |
| Proceeds from issuance of common stock-The2024Inducement Offer | - | 0 | - | - |
| Proceeds from issuance of common stock and other equity-classified contracts from the september 2024 public offering, net of issuance costs | - | - | 2,174 | 1,570 |
| Proceeds from issuance of common stock-Atm Offering | - | 3,751 | - | - |
| Proceeds from notes payable due to related parties | - | 0 | 300 | 0 |
| Proceeds from issuance of common stock and equity-classified contracts, net of issuance costs | 3,731 | - | - | - |
| Proceeds from issuance of convertible notes payable | - | 300 | - | - |
| Proceeds from exercise of warrants (see note 12) | 401 | 0 | - | - |
| Payments on short-term notes payable | 499 | 61 | 26 | 151 |
| Payments on deferred financing costs | - | - | - | 0 |
| Proceeds from notes payable | 835 | 61 | 0 | - |
| Net cash provided by (used in) financing activities | 4,468 | 307 | 2,448 | 2,589 |
| Net change in cash and cash equivalents | 353 | -987 | 237 | -2,035 |
| Cash and cash equivalents, beginning of period | 88 | 1,075 | 2,873 | - |
| Cash and cash equivalents, end of period | 441 | 88 | 1,075 | - |
Catheter Precision, Inc. (VTAK)
Catheter Precision, Inc. (VTAK)